<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21231">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02830477</url>
  </required_header>
  <id_info>
    <org_study_id>18559</org_study_id>
    <secondary_id>KV1601</secondary_id>
    <nct_id>NCT02830477</nct_id>
  </id_info>
  <brief_title>Study Evaluating &quot;Real World&quot; Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis</brief_title>
  <acronym>TAURUS</acronym>
  <official_title>A Multinational Phase IV Study Evaluating &quot;Real World&quot; Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate weekly prophylaxis dosing regimens
      used in standard clinical practice.

      In addition the study will capture reported bleed rate, pattern of change in KOVALTRY
      prophylaxis dose &amp; dosing frequency, reason for choice of treatment regimen, FVIII product
      switch pattern, patient treatment satisfaction and adherence, KOVALTRY pharmacokinetic data
      (if performed), KOVALTRY consumption, as well as safety data.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, prospective, non-interventional, single arm study in patients receiving KOVALTRY
      as prophylaxis therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2016</start_date>
  <completion_date type="Anticipated">September 3, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients on 2x weekly prophylaxis</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients on 3x weekly prophylaxis</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite number of reported bleeds (total, spontaneous, joint and trauma)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in predefined prophylaxis regimen per age group and per country</measure>
    <time_frame>At the end of observational period, up to 12 months maximum</time_frame>
    <description>Age group:
0- &lt;6 years
6 - 12 years
13 - &lt;18 years
&gt; 18 years
Weekly prophylaxis dosing regimens:
2 injections a week
3 injections a week
Injected on every other day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall prophylaxis dose IU/kg in patients per age group and per country</measure>
    <time_frame>At the end of observational period, up to 12 months maximum</time_frame>
    <description>Age group:
0- &lt;6 years
6 - 12 years
13 - &lt;18 years
&gt; 18 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of physicians who selected the individual criteria as top 3 reason for the prophylaxis decision</measure>
    <time_frame>At baseline</time_frame>
    <description>Physician will select top 3 reasons from Age, i.v. access, Current treatment regimen, Bleeding history with current treatment regimen, Prior history of life threatening bleed, Number of target joints, Pharmacokinetic data, Adherence/Compliance history, Activity level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and median composite score for treatment satisfaction (Hemo-SAT)</measure>
    <time_frame>At baseline and end of observational period, up to 12 months maximum</time_frame>
    <description>Hemo-SAT - Hemophilia treatment satisfaction questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score for treatment adherence (VERITAS-PRO)</measure>
    <time_frame>At baseline, 6 months and end of observational period, up to 12 months maximum</time_frame>
    <description>VERITAS - Validated Hemophilia Regimen Treatment Adherence Scale-Prophylaxis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of events of special interest, such as inhibitors</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of physicians used one or more predefined KOVALTRY PK parameter(s) to define the dose in clinical practice</measure>
    <time_frame>At routine visits, up to 12 months maximum</time_frame>
    <description>Pharmacokinectic parameters
Area under the curve (AUC)
Clearance (Cl)
Half-life
FVIII trough
FVIII peak levels
In-vivo recovery</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Hemophilia A, Congenital</condition>
  <arm_group>
    <arm_group_label>BAY81-8973</arm_group_label>
    <description>Previously treated patients receiving IV infusion of KOVALTRY for routine prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973</intervention_name>
    <description>unmodified, full length recombinant FVIII</description>
    <arm_group_label>BAY81-8973</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Previously treated male patients with moderate to severe (≤ 5% FVIII:C) hemophilia A, with
        ≥ 50 exposure days (EDs) to any FVIII product and no history of inhibitors who have been
        prescribed KOVALTRY for a medically appropriate use will be eligible to be included into
        this study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients diagnosed with moderate to severe hemophilia A (≤ 5% Factor VIII
             levels)

          -  Any age

          -  ≥ 50 exposure days (EDs) to any FVIII product

          -  Patients with no history of inhibitors

          -  Currently on (started within 3 months of study enrollment) or plan to start
             prophylaxis therapy with KOVALTRY

          -  Written informed consent

        Exclusion Criteria:

          -  Patients participating in an investigational program with interventions outside of
             routine clinical practice

          -  Patients with an additional diagnosis of any bleeding/coagulation disorder other than
             hemophilia A
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 27, 2017</lastchanged_date>
  <firstreceived_date>June 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Previously treated patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
